Whitnell & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

Whitnell & Co’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$4K	Hold	500	–	–	﹤0.01%	263
2019 Q3	$2K	Hold	500	–	–	﹤0.01%	264
2019 Q2	$1K	Hold	500	–	–	﹤0.01%	247
2019 Q1	$1K	Hold	500	–	–	﹤0.01%	251
2018 Q4	$1K	Hold	500	–	–	﹤0.01%	244
2018 Q3	$2K	Hold	500	–	–	﹤0.01%	246
2018 Q2	$3K	Hold	500	–	–	﹤0.01%	284
2018 Q1	$4K	Hold	500	–	–	﹤0.01%	298
2017 Q4	$4K	Hold	500	–	–	﹤0.01%	260
2017 Q3	$5K	Hold	500	–	–	﹤0.01%	223
2017 Q2	$6K	Hold	500	–	–	﹤0.01%	224
2017 Q1	$5K	Buy	+500	New	+$5K	﹤0.01%	242
2016 Q4	–	Sell	-500	Closed	-$6K	–	384
2016 Q3	$6K	Hold	500	–	–	﹤0.01%	276
2016 Q2	$5K	Hold	500	–	–	﹤0.01%	291
2016 Q1	$6K	Hold	500	–	–	﹤0.01%	266
2015 Q4	$6K	Hold	500	–	–	﹤0.01%	285
2015 Q3	$8K	Hold	500	–	–	﹤0.01%	245
2015 Q2	$11K	Hold	500	–	–	﹤0.01%	222
2015 Q1	$9K	Hold	500	–	–	﹤0.01%	228
2014 Q4	$9K	Hold	500	–	–	﹤0.01%	239
2014 Q3	$7K	Hold	500	–	–	﹤0.01%	239
2014 Q2	$8K	Hold	500	–	–	﹤0.01%	245
2014 Q1	$7K	Hold	500	–	–	﹤0.01%	247
2013 Q4	$4K	Hold	500	–	–	﹤0.01%	251
2013 Q3	$3K	Hold	500	–	–	﹤0.01%	250
2013 Q2	$3K	Buy	+500	New	+$2.58K	﹤0.01%	356

Other funds holding AVDL

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Whitnell & Co's AVDL Position: Q4 2019 in Review

Whitnell & Co held its Avadel Pharmaceuticals (AVDL) position steady in Q4 2019 at 500 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Whitnell & Co first reported a position in AVDL in Q2 2013 and has held it in 26 quarters since. The position peaked at $11K in Q2 2015. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

Whitnell & Co held 500 shares of Avadel Pharmaceuticals worth $4K as of Q4 2019.
Whitnell & Co left its Avadel Pharmaceuticals share count unchanged in Q4 2019.
Avadel Pharmaceuticals made up ﹤0.01% of Whitnell & Co's portfolio in Q4 2019, its #263 holding.
Whitnell & Co first reported a position in Avadel Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
Whitnell & Co's Avadel Pharmaceuticals position peaked at $11K in Q2 2015.
42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on Whitnell & Co's 13F filing for Q4 2019, filed 11 Feb 2020.